Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-101 in advanced cancers
NCT03195699Phase 1Completed
- Sponsor
- Tvardi Therapeutics
- Start
- Nov 2017
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tti-101 in cancer, breast cancer, head and neck squamous cell carcinoma (HNSCC) and 5 more (4 arms), sponsored by Tvardi Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Maximum Plasma Concentration at 18 months and 2 more. Started Nov 2017; status: completed.
02
Drugs
tti-101
03
Conditions
cancerbreast cancerhead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03195699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195699.